Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | PLA2G2A | P14555 | 7/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | DHODH | Q02127 | 1/20 | 0.40 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15919454 | 0.91 | SMN1; SMN2 (0.57) | SMN1; SMN2CYP1A2PLA2G2AALDH1A1POLB | |
| SCHEMBL15905018 | 0.90 | ALDH1A1 (0.43) | SMN1; SMN2CYP1A2ALDH1A1POLBLMNA | |
| SCHEMBL15919272 | 0.88 | PLA2G2A (0.46) | SMN1; SMN2CYP1A2PLA2G2AALDH1A1POLB | |
| SCHEMBL15919267 | 0.87 | ACACB (0.45) | SMN1; SMN2CYP1A2PLA2G2AALDH1A1POLB | |
| SCHEMBL17323668 | 0.86 | PLA2G2A (0.47) | SMN1; SMN2CYP1A2PLA2G2AALDH1A1KDM4E | |
| SCHEMBL15919477 | 0.85 | ALDH1A1 (0.44) | SMN1; SMN2CYP1A2PLA2G2AALDH1A1POLB | |
| SCHEMBL15919455 | 0.83 | SMN1; SMN2 (0.56) | SMN1; SMN2CYP1A2ALDH1A1POLBLMNA | |
| SCHEMBL15904787 | 0.81 | POLB (0.53) | SMN1; SMN2CYP1A2ALDH1A1POLBLMNA | |
| Hydrochloric Acid SCHEMBL17313789 | 0.80 | POLB (0.52) | SMN1; SMN2CYP1A2ALDH1A1POLBLMNA | |
| SCHEMBL15919456 | 0.79 | POLB (0.53) | SMN1; SMN2CYP1A2ALDH1A1POLBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9663488-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-9663488-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-20150353546-A1 | METALLOENZYME INHIBITOR COMPOUNDS | Viamet Pharmaceuticals (NC), Inc. | 2015-12-10 | — | — | US | disclosed |
| US-20150353546-A1 | METALLOENZYME INHIBITOR COMPOUNDS | Viamet Pharmaceuticals (NC), Inc. | 2015-12-10 | — | — | US | disclosed |
| WO-2014117090-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2014-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353546-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | SMN1; SMN2 1142/4885CYP1A2 462/4885PLA2G2A 1990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.